Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second
line therapy in patients with stage IV, metastatic breast cancer